checkAd
    Startseite > Aktien > Akero Therapeutics > Nachrichten
    Akero Therapeutics Aktie
    20,480
     
    EUR
    -0,36 %
    -0,075 EUR
    Letzter Kurs 07.05.24 Lang & Schwarz
    20,230
     
    EUR
    352 STK
    Geldkurs 07.05.24
    20,730
     
    EUR
    352 STK
    Briefkurs 07.05.24
    ISIN: US00973Y1082 · WKN: A2PLNP · USA

    Neueste Nachrichten

    Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Akero Therapeutics, Inc. (AKRO) Investors
    07.05.24 · Business Wire (engl.) · Akero Therapeutics
    The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Akero Therapeutics, Inc. (AKRO) Investors
    06.05.24 · Business Wire (engl.) · Akero Therapeutics
    INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Akero Therapeutics, Inc. (AKRO) Investors
    06.05.24 · Business Wire (engl.) · Akero Therapeutics
    Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Akero Therapeutics, Inc. (AKRO) on Behalf of Investors
    03.05.24 · Business Wire (engl.) · Akero Therapeutics
    Akero Therapeutics, Inc. (AKRO) Investor Notice: Robbins LLP Reminds Stockholders of the Akero Therapeutics, Inc. Class Action
    03.05.24 · Business Wire (engl.) · Akero Therapeutics
    INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Akero Therapeutics, Inc. (AKRO) on Behalf of Investors
    02.05.24 · Business Wire (engl.) · Akero Therapeutics
    AKRO INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Akero Therapeutics, Inc. and Announces Opportunity for Investors with Substantial Losses to Lead Class Action Lawsuit
    02.05.24 · Business Wire (engl.) · Akero Therapeutics
    The Law Offices of Frank R. Cruz Announces Investigation of Akero Therapeutics, Inc. (AKRO) on Behalf of Investors
    02.05.24 · Business Wire (engl.) · Akero Therapeutics
    NASDAQ: AKRO: Kessler Topaz Meltzer & Check, LLP Notifies Investors of a Securities Class Action Lawsuit Filed Against Akero Therapeutics, Inc.
    01.05.24 · Business Wire (engl.) · Akero Therapeutics
    Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer
    30.04.24 · globenewswire · Akero Therapeutics
    ROSEN, LEADING INVESTOR COUNSEL, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AKRO
    29.04.24 · Business Wire (engl.) · Akero Therapeutics
    AKRO INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Akero Therapeutics, Inc. and Announces Opportunity for Investors with Substantial Losses to Lead Class Action Lawsuit
    29.04.24 · Business Wire (engl.) · Akero Therapeutics